Novel drug has been linked to increased mortality, but UC San Diego scientists find no statistically significant evidence in study comparing pimavanserin (Nuplazid) to another drug and to combination therapy UNIVERSITY OF CALIFORNIA – SAN DIEGO In the wake of media and public reports about increased mortality linked to a new drug for treating Parkinson’s...
Tag: <span>parkinsons</span>
Post
Genomic dark matter activity connects Parkinson’s and psychiatric diseases
Comprehensive study reveals an expanding universe of ‘darkest of the dark matter‘ RNAs in dopamine-producing cells in our brains BRIGHAM AND WOMEN’S HOSPITAL Dopamine neurons are located in the midbrain, but their tendril-like axons can branch far into the higher cortical areas, influencing how we move and how we feel. New genetic evidence has revealed that these...
Post
Early Parkinson’s patients waiting too long to seek medical evaluation
The time between diagnosis and the institution of symptomatic treatment is critical in the effort to find a cure for Parkinson’s Disease (PD). A paper published in Nature Partner Journal: Parkinson’s Disease notes too many early PD patients wait too long before seeking medicalattention, or start taking symptomatic medications before they are required, thereby dramatically shrinking the pool of candidates for clinical trials. Figure 1. Relationship between time of diagnosis,...
Post
Magnetic gene in fish may someday help those with epilepsy, Parkinson’s
EAST LANSING, Mich. — An aquarium fish that senses the Earth’s magnetic field as it swims could help unlock how the human brain works and how diseases such as Parkinson’s and other neurological disorders function. Michigan State University scientists are the first to discover a navigational gene in glass catfish called the electromagnetic-perceptive gene, or...
Post
Study: The eyes may have it, an early sign of Parkinson’s disease
Thinning of retina linked to loss of brain cells that control movement AMERICAN ACADEMY OF NEUROLOGY MINNEAPOLIS – The eyes may be a window to the brain for people with early Parkinson’s disease. People with the disease gradually lose brain cells that produce dopamine, a substance that helps control movement. Now a new study has...
Post
Insulin resistance under-diagnosed in non-diabetics with Parkinson’s disease
Findings could lead to increased screening for PD patients to detect and correct insulin resistance, reports the Journal of Parkinson’s Disease IOS PRESS Amsterdam, NL, August 2, 2018 – Almost two-thirds of non-diabetic patients with Parkinson’s disease (PD) may be insulin resistant, despite having normal blood sugar, report scientists in the Journal of Parkinson’s Disease. Their findings suggest...
Post
Parkinson’s gene affects more people than previously thought
New research finds that a gene previously thought to affect only a small percentage of Parkinson’s disease cases actually affects many more. The findings mean that treatments that are being developed for a small number of people may, in fact, benefit many more. Almost 1 million people in the United States and nearly 10 million people across the world...
Post
Contact sports increase Parkinson’s disease risk
By Maria Cohut Fact checked by Jasmin Collier Injuries from playing contact sports, such as rugby, boxing, and martial arts, have been linked to a heightened risk of dementia. A new study now says that contact sports may actually lead to other neurodegenerative diseases, and it explains why. A new study argues that contact sports...
Post
Study provides insight into how dying neurons control eating behaviors of the brain microglia
July 23, 2018, The Mount Sinai Hospital A new Mount Sinai study, published July 23 in the journal Nature Neuroscience, provides important insight into how microglia, cells that form a branch of the immune system inside the brain, go about their job of clearing out dying and non-functional neurons—and how they sometimes mistakenly attack healthy neurons, an...
Post
Drug now in clinical trials for Parkinson’s strengthens heart contractions in animals
JOHNS HOPKINS MEDICINE A drug currently in clinical trials for treating symptoms of Parkinson’s disease may someday have value for treating heart failure, according to results of early animal studies by Johns Hopkins Medicine researchers. The drug, a member of a class of compounds known as phosphodiesterase (PDE) type I inhibitors, shows promising effects on...